공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세포성 종양 항체 P53(종양억제제 P53 또는 항체 NY-CO-13) : 파이프라인 리뷰

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 358696
페이지 정보 영문 134 Pages
가격
US $ 3,500 ₩ 3,873,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,746,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,619,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세포성 종양 항체 P53(종양억제제 P53 또는 항체 NY-CO-13) : 파이프라인 리뷰 Cellular Tumor Antigen p53 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 134 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 세포성 종양 항체 P53(종양억제제 P53 또는 항체 NY-CO-13) 치료용 파이프라인 제품의 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 질환 및 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

  • 서론
    • 분석 범위
  • 세포성 종양 항체 P53(종양억제제 P53/항체 NY-CO-13)의 개요
  • 치료제 개발
    • 임상시험중인 제품 : 임상시험 단계별
    • 임상시험중인 제품 : 치료 영역별
    • 임상시험중인 제품 : 증상별
  • 파이프라인 제품의 개요
    • 임상시험 후기 단계 제품
    • 임상시험 초기 단계 제품
  • 각 기업에서 개발중인 제품
  • 각 대학/연구기관에서 개발중인 제품
  • 치료제 평가
    • 단일요법 치료제/병용 치료제의 경우
    • 작용기서별
    • 투약 경로별
    • 분자 종류별
  • 세포성 종양 항체 P53(종양억제제 P53/항체 NY-CO-13) 치료제 개발에 참여하고 있는 기업
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Pharma SA
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • 약제 개요
    • Adxs-LmddA159
      • 제품 개요
      • 작용기서
      • 연구개발(R&D)의 진행 상황
    • AG-1101
    • APR-017
    • APR-246
    • ATRN-502
    • cenersen sodium
    • contusugene ladenovec
    • COTI-2
    • D-12PGJ3
    • 두경부 편평세포암용 향p53 활성화용 유전자 치료
    • 종양용 p53 활성화용 유전자 치료
    • KM-3174
    • MHY-449
    • MJ-05
    • MX-225
    • N-2
    • 종양용 p53 활성화용 종양용해성 바이러스
    • OSE-2101
    • p28
    • QPAL-1
    • QPI-1002
    • p53 활성화를 위한 유전자재조합형 단백질
    • SGT-53
    • SL-801
    • p53 활성화를 위한 소분자
    • 암·바이러스성 감염증용 p53 활성화 소분자
    • 흑색종용 p53 활성화 소분자
    • 종양용 세포성 종양 항체 p53을 표적으로 하는 백신
    • ZMC-1
  • 개발 휴지 상태 프로젝트
  • 개발이 중지된 프로젝트
  • 주목해야 할 최신 동향·프레스 릴리스(총 10건)
  • 부록

도표

KSA 16.07.25

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Actavalon Inc, H2 2019
  • Pipeline by ADRx Inc, H2 2019
  • Pipeline by Affina Biotechnologies Inc, H2 2019
  • Pipeline by Aprea Therapeutics AB, H2 2019
  • Pipeline by BlinkBio Inc, H2 2019
  • Pipeline by CanBas Co Ltd, H2 2019
  • Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
  • Pipeline by Innovation Pharmaceuticals Inc, H2 2019
  • Pipeline by ISA Pharmaceuticals BV, H2 2019
  • Pipeline by LynkCell Inc, H2 2019
  • Pipeline by MultiVir Inc, H2 2019
  • Pipeline by ORCA Therapeutics BV, H2 2019
  • Pipeline by OSE Immunotherapeutics, H2 2019
  • Pipeline by Pharos I&BT Co Ltd, H2 2019
  • Pipeline by PMV Pharmaceuticals Inc, H2 2019
  • Pipeline by Quark Pharmaceuticals Inc, H2 2019
  • Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2019
  • Pipeline by SynerGene Therapeutics Inc, H2 2019
  • Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2019
  • Pipeline by Z53 Therapeutics LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Dormant Products, H2 2019 (Contd..4), H2 2019
  • Dormant Products, H2 2019 (Contd..5), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2019, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 7, 2, 7, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Esophageal Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Pancreatic Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Blood Cancer, Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Delayed Graft Function (DGF), Endometrial Cancer, Gastrointestinal Tumor, Gliosarcoma, Hepatic - Colorectal Metastasis, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
  • Actavalon Inc
  • ADRx Inc
  • Affina Biotechnologies Inc
  • Aprea Therapeutics AB
  • BlinkBio Inc
  • CanBas Co Ltd
  • Cotinga Pharmaceuticals Inc
  • Innovation Pharmaceuticals Inc
  • ISA Pharmaceuticals BV
  • LynkCell Inc
  • MultiVir Inc
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Pharos I&BT Co Ltd
  • PMV Pharmaceuticals Inc
  • Quark Pharmaceuticals Inc
  • Shenzen SiBiono GeneTech Co Ltd
  • SynerGene Therapeutics Inc
  • Tara Immuno-Oncology Therapeutics LLC
  • Z53 Therapeutics LLC
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
  • Adp-53DCV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APR-246 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APR-548 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AU-14022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • contusugene ladenovec - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • COTI-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q